Advanced

In vivo detection of alzheimer’s disease

Leuzy, Antoine; Heurling, Kerstin; Ashton, Nicholas J.; Schöll, Michael LU and Zimmer, Eduardo R. (2018) In Yale Journal of Biology and Medicine 91(3). p.291-300
Abstract

Recent revisions to the diagnostic criteria for Alzheimer’s disease (AD†) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodromal AD, mild cognitive impairment) and dementia phases. The role of biological markers (biomarkers) of both the underlying molecular pathologies and related neurodegenerative changes has also been acknowledged. In this abridged review, we provide an overview of fluid (cerebrospinal fluid and blood) and molecular imaging-based biomarkers used within the field and discuss the potential role of computer driven artificial intelligence approaches... (More)

Recent revisions to the diagnostic criteria for Alzheimer’s disease (AD†) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodromal AD, mild cognitive impairment) and dementia phases. The role of biological markers (biomarkers) of both the underlying molecular pathologies and related neurodegenerative changes has also been acknowledged. In this abridged review, we provide an overview of fluid (cerebrospinal fluid and blood) and molecular imaging-based biomarkers used within the field and discuss the potential role of computer driven artificial intelligence approaches for both the early and accurate identification of AD and as a tool for population enrichment in clinical trials testing candidate disease modifying therapies.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer’s disease, Diagnosis, Fluid biomarkers, Medical imaging
in
Yale Journal of Biology and Medicine
volume
91
issue
3
pages
10 pages
publisher
Yale Journal of Biology and Medicine Inc.
external identifiers
  • scopus:85054066481
ISSN
0044-0086
language
English
LU publication?
yes
id
e23c3653-2c8c-42d5-ab5a-2183e66f546a
alternative location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153625/
date added to LUP
2018-10-15 14:23:29
date last changed
2019-10-15 06:48:02
@article{e23c3653-2c8c-42d5-ab5a-2183e66f546a,
  abstract     = {<p>Recent revisions to the diagnostic criteria for Alzheimer’s disease (AD†) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodromal AD, mild cognitive impairment) and dementia phases. The role of biological markers (biomarkers) of both the underlying molecular pathologies and related neurodegenerative changes has also been acknowledged. In this abridged review, we provide an overview of fluid (cerebrospinal fluid and blood) and molecular imaging-based biomarkers used within the field and discuss the potential role of computer driven artificial intelligence approaches for both the early and accurate identification of AD and as a tool for population enrichment in clinical trials testing candidate disease modifying therapies.</p>},
  author       = {Leuzy, Antoine and Heurling, Kerstin and Ashton, Nicholas J. and Schöll, Michael and Zimmer, Eduardo R.},
  issn         = {0044-0086},
  keyword      = {Alzheimer’s disease,Diagnosis,Fluid biomarkers,Medical imaging},
  language     = {eng},
  number       = {3},
  pages        = {291--300},
  publisher    = {Yale Journal of Biology and Medicine Inc.},
  series       = {Yale Journal of Biology and Medicine},
  title        = {In vivo detection of alzheimer’s disease},
  volume       = {91},
  year         = {2018},
}